Market Overview
Antidepressants
Market is projected to achieve a value of USD 17,243 Million in 2023, with a
linear behavior in the market growth it is forecasted to achieve a value of USD
23,423 Million by 2033 with a CAGR of 6% during the forecast period 2023-2033.
Antidepressants
are drugs used in the management of a range of mood disorders, with a primary
focus on alleviating depression. Their mechanism of action involves restoring
equilibrium among the brain's neurotransmitters, including serotonin,
norepinephrine, and dopamine, all of which play a pivotal role in mood
regulation. These medications are typically prescribed to address conditions
such as major depressive disorder, various anxiety disorders, and
post-traumatic stress disorder. It's important to note that antidepressants
don't offer immediate relief and may take several weeks to manifest their
complete therapeutic benefits.
Antidepressants
which contain wide range of medications such as Selective Serotonin Reuptake
Inhibitors, Serotonin & Norepinephrine Reuptake Inhibitors, Atypical
Antidepressants, Tricyclic Antidepressants. Increasing prevalence of
depression, growing awareness and acceptance of mental health disorders,
increasing infrastructure investment, increasing new drug launches and product
approvals, increasing research funding by key market players propel the market
growth. Additionally, increasing the number of people suffering from depression
contributing to drive the antidepressants market growth.
For instance, according
to the World Health Organization (WHO) in September 2021, it was reported that
depression is a common mental health condition. According to estimates,
approximately 5.0% of adults globally suffer from depression.
Moreover, in
countries like the United Kingdom and the United States, known for their
dynamic and rapidly growing economies, the prevalence of depression is
significant across all age groups. For instance, based on data released by the
Anxiety and Depression Foundation in January 2022, it was reported that
generalized anxiety disorder impacts approximately 6.8 million adults each
year, accounting for about 3.1% of the U.S. population. This substantial
prevalence is anticipated to be a key driver for overall antidepressants market
growth during the projected period.
COVID 19
pandemic has a long term and short term impact on every individual mental
health. The pandemic has resulted in increased stress levels among the general
population due to various factors, including financial strain, emotional
burdens, stress, anxiety, and fear. Consequently, there has been a notable
increase in the prevalence of depression upsurge the market growth.
Market Scope
Report Attributes |
Description |
Market Size in 2022 |
USD 16,279 Million |
Market Forecast in 2033 |
USD 23,423 Million |
CAGR % 2023-2033 |
6% |
Base Year |
2022 |
Historic Data |
2016-2022 |
Forecast Period |
2023-2033 |
Report USP |
Production,
Consumption, company share, company heatmap, company production capacity,
growth factors and more |
Segments Covered |
By Drug Class, By Disorder, By
Distribution Channel |
Regional Scope |
North America,
Europe, APAC, South America and Middle East and Africa |
Country Scope |
U.S.; Canada; U.K.; Germany;
France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan;
South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi
Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies |
Teva
Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Sanofi, AstraZeneca, Eli
Lilly and Company, Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb. |
Market Dynamics
The Antidepressants
Market is driven the increasing occurrence of mental disorders, such as
depression, along with a growing global focus on early and prompt diagnosis, is
leading to a substantial number of patients in need of treatment. This surge in
patient numbers is driving the demand for novel and inventive medications in
the global market. For instance, as per World Health Organization (WHO),
approximately 7.5% of the population in India is affected by various forms of
mental disorders annually. Moreover, an estimated 56 million individuals in the
country experience depression each year.
Moreover, the
increasing focus on research and development efforts by key market players to
introduce novel and inventive treatment options, along with robust support from
international and government healthcare organizations in terms of funding, is
anticipated to propel the growth of the global antidepressants market.
Additionally, the positive marketing approval for new innovative medicines
stimulate the market growth over the forecast period. For instance, In May
2020, Allergan made an announcement about its acquisition of an investigational
NMDA drug from Aptinyx, along with their additional portfolio, in a deal valued
at USD 560 million.
Furthermore, regional
and national healthcare agencies, along with for-profit organizations and
governments, are collaborating to raise awareness among the general population
regarding various mental health conditions and the treatment alternatives that
are accessible. These entities are championing mental health awareness through
diverse campaigns, resulting in increased rates of diagnosis and treatment in
both developed and emerging countries.
Traditional
treatments and pharmaceuticals for depression and other mental disorders have
historically been assessed for their adverse effects, often impacting not only
the intended neurological targets but also normal cells in the body.
Consequently, many patients experience a range of side effects, such as weight
gain, dizziness, and blurred vision. These side effects restrain the growth of
market.
Overall, with
the help of existing and combination treatment therapy the Antidepressants
Market is expected to witness significant growth in the coming years, driven by
the introduction of new therapies and an increasing demand for effective
treatments. Additionally, there is a need for advance and effective research
and development to address the unmet needs of Antidepressants treatment and to
develop safe and effective therapies with lower side effects.
Market Drug Class Analysis
By Drug Class,
the Antidepressants Market is Categories into Selective Serotonin Reuptake
Inhibitors, Serotonin & Norepinephrine Reuptake Inhibitors, Atypical
Antidepressants, Tricyclic Antidepressants. The Selective Serotonin Reuptake
Inhibitors segment accounts for the largest share of around 36% of in 2022.
The clinical
superiority of Selective Serotonin Reuptake Inhibitors (SSRIs) over traditional
drugs in the management and treatment of depression, coupled with the robust
pipeline of major industry players assessing new potential candidates within
this drug category, is positioned to support the expansion of this segment.
Market By Disorder Analysis
By Disorder, the
Antidepressants Market is Categories into Major Depressive Disorder,
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder. The Major
Depressive Disorder segment accounts for the largest share of around 40% of the
Market in 2022.
The increasing
awareness, growing prevalence of disorder, rising awareness towards treatment
and management of depression among younger population driving the growth of
segment.
Obsessive-compulsive
disorder (OCD) is expected to hold a relatively smaller market share. This is
primarily due to lower rates of diagnosis and treatment among individuals
dealing with OCD, which contributes to the segment's reduced presence in the
global market.
Market Distribution Channel Analysis
By Distribution
Channel, the Antidepressants Market is Categories into Hospital Pharmacies,
Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment
accounts for the largest share of around 54% of the Market in 2022.
Rising
investment in healthcare and increasing hospital facility in developed and
developing market are major factor to drive the segment. Moreover, Hospitals
are the primary healthcare facility where patient come for treatment. Also
hospital having the infrastructure to diagnosis and advance treatment option.
However, increasing
popularity and preference of patient towards retail pharmacy accountable for
the growth of retail segment.
Market Regional Analysis
North America
dominate the Antidepressants Market with the highest revenue generating market
with share of more than 42%. The North America dominate this market due to the rising
prevalence of depression in US, easy availability of medications, new products
launch. Additionally, strong presence of market player, well developed infra
structure, higher number of research favor growth of region. For instance, as
per data from the Anxiety & Depression Association of America (ADAA), major
depressive disorder (MDD) impacts approximately 6.7% of the entire adult population
(ages 18 and older) in the United States each year.
Europe having
the second-largest market share in Antidepressants Market due to focus on
R&D on Antidepressants found in Europe, the rising demand for targeted
medication. Moreover, government policies and increasing the elder population
in the region significantly contribute to expand the market.
Asia-Pacific is
estimated the fastest growing CAGR in Market in forecasted period. This is due
to increasing in healthcare expenditure and the rise in research and
development activities in the pharmaceutical sector.
Competitive Analysis
The Antidepressants
Market is dominated by a few large companies, such as Teva Pharmaceutical
Industries Ltd., GlaxoSmithKline PLC, Sanofi, AstraZeneca, Eli Lilly and Company,
Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb.
There Are Some Of The Recent Developments Of The Antidepressants
Market:
April 2022- In a
head-to-head study, Lundbeck's antidepressant vortioxetine, marketed under the
brand names Trintellix and Brintellix, showed an advantage over desvenlafaxine,
which Pfizer markets as Pristiq in the United States. The study examined the
effectiveness of vortioxetine in patients with Major Depressive Disorder (MDD)
who had only partially responded to treatment with selective serotonin reuptake
inhibitors (SSRIs) in comparison to desvenlafaxine.
August 2022- The
U.S. Food and Drug Administration (FDA) granted approval for
dextromethorphan-bupropion, known as Auvelity and developed by Axsome
Therapeutics, as a medication for treating major depressive disorder in adults.
Notably, it is the first drug of its kind to demonstrate effectiveness within
one week of administration.
By Drug Class
·
Selective Serotonin Reuptake
Inhibitors
·
Serotonin & Norepinephrine Reuptake
Inhibitors
·
Atypical Antidepressants
·
Tricyclic Antidepressants
By Disorder
·
Major Depressive Disorder
·
Obsessive-Compulsive Disorder
·
Generalized Anxiety Disorder
By Distribution Channel
·
Hospital Pharmacies
·
Retail Pharmacies
· Online Pharmacies
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
Antidepressants Market was valued at USD 16,279 million in 2022 and is estimated to grow at a CAGR of 6%.
Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Sanofi, AstraZeneca, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb
North America dominates the market with an active share of 42%, while North America is estimated to grow at a higher CAGR of 2.1%.
Only Three Thousand Four Hundred Ninety Nine US dollar
Only Four Thousand Four Hundred Ninety Nine US dollar
Only Five Thousand Four Hundred Ninety Nine US dollar